Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.71 USD
-0.05 (-2.84%)
Updated Aug 27, 2024 04:00 PM ET
Pre-Market: $1.71 0.00 (0.00%) 8:16 AM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
ESPR 1.71 -0.05(-2.84%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
Other News for ESPR
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
Esperion Therapeutics: Strategically Positioned To Grow
Esperion management to meet with Jefferies
Esperion management to meet with Jefferies